India Authorizes Indigenously Developed Protein Sub-unit COVID-19 Vaccine for Teenagers

India-based Biological E. Limited announced its CorbeVax COVID-19 vaccine had received emergency use authorization from India's drug regulator for the 12 to 18-year age group.

The Drugs Controller General of India had already approved CorbeVax for 'restricted' use in emergency situations among adults on December 28, 2021.

CorobeVax is India's first indigenously developed Receptor Binding Domain Protein sub-unit vaccine against COVID-19.

The combination of Alum with Dynavax Technologies's CpG with N1C1 antigen elicited a highly synergistic, balanced immune response in preclinical models. 

Ms. Mahima Datla, Managing Director, Biological E. Limited, said in a company issued a press release on February 21, 2022, "We are pleased with this significant development, which helps extend the reach of our vaccine to the age group of 12 to 18 years in our country."

The vaccine antigen's initial construct and production process were developed at Texas Children's Hospital CVD, located in Houston, Texas, and in-licensed from BCM Ventures. 

Biological E. Limited is a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953.